What is the Marksans Pharma PE ratio today?
Marksans Pharma's PE ratio is 27.7 at the 29 October 2026 close (₹315.35 a share): a market capitalisation of ₹14,290 crore divided by consolidated net profit attributable to shareholders of ₹517 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹418 crore) it is 34.2.
What is the Marksans Pharma PB ratio (price to book value)?
Marksans Pharma's price-to-book (PB) ratio is 4.73 at the 29 October 2026 close: a market capitalisation of ₹14,290 crore divided by shareholders' equity (book value) of ₹3,023 crore on 31 March 2026. That is a book value of ₹66.71 per share against a share price of ₹315.35.
What is the Marksans Pharma debt to equity ratio?
Marksans Pharma's debt-to-equity ratio was 0.01 on 31 March 2026: borrowings of ₹29.6 crore against total equity of ₹3,053 crore. A year earlier, on 31 March 2025, it was 0.01.
What is the Marksans Pharma market cap?
Marksans Pharma's market capitalisation was ₹14,290 crore at the 29 October 2026 close: 45.32 crore shares at ₹315.35 each.
What is the Marksans Pharma EPS?
Marksans Pharma's basic earnings per share (EPS) were ₹9.22 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹11.41.
What is the Marksans Pharma dividend in 2026 and its record date?
In 2026, Marksans Pharma has declared one dividend: ₹0.90 with record date 20 August 2026.
Is Marksans Pharma debt free?
No. Marksans Pharma had borrowings of ₹29.6 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.01. Its cash and current investments were ₹990 crore, so it held net cash of ₹960 crore.
What is the Marksans Pharma net worth?
Marksans Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹3,023 crore on 31 March 2026. Its market value is a different figure: a market capitalisation of ₹14,290 crore at the 29 October 2026 close.
What is the Marksans Pharma promoter holding?
Promoters held 43.87% of Marksans Pharma on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Marksans Pharma ROE and ROCE?
In FY26, Marksans Pharma's return on equity (ROE) was 25.6% and its return on capital employed (ROCE) was 27.8%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 3.3% and ROCE 3.5%.
What is the Marksans Pharma shareholding pattern?
On 30 September 2026, Marksans Pharma's shares were held by promoters 43.87%, foreign portfolio investors (FII/FPI) 19.06%, domestic institutions (DII) 5.54% (including mutual funds at 3.72%) and retail and other non-institutional investors 31.53%. Over the year, FII holding was up 2.14 percentage points from 16.92% and DII holding was up 0.26 percentage points from 5.28%.
What are the Marksans Pharma latest quarterly results?
Marksans Pharma's latest results are for Q1 FY27 (April–June 2026), filed on 12 August 2026: consolidated net profit attributable to shareholders ₹157 crore, up 169.5% from ₹58.3 crore in Q1 FY26; revenue from operations ₹841 crore, up 35.6% year on year.
What is the Marksans Pharma book value per share?
Marksans Pharma's book value per share was ₹66.71 on 31 March 2026: shareholders' equity of ₹3,023 crore divided by the 45.32 crore shares in issue. The share price at the 29 October 2026 close was ₹315.35.
What is the Marksans Pharma dividend yield?
Marksans Pharma's dividend yield is 0.29% at the 29 October 2026 close: dividends of ₹0.90 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹315.35. They were ₹0.90 on 20 August 2026.
What is the Marksans Pharma free cash flow?
In FY26, Marksans Pharma generated ₹458 crore of cash from operations and spent ₹131 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹328 crore. In FY25 it was ₹3.4 crore.
What is the Marksans Pharma revenue and profit in FY26?
In FY26 (April 2025–March 2026), Marksans Pharma's consolidated net profit attributable to shareholders was ₹418 crore, up 992.2% from ₹38.3 crore in FY25, on revenue from operations of ₹2,951 crore. Over three years, from FY23, net profit was up 56.9%.
When are the Marksans Pharma next results?
Marksans Pharma will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, the date of the board meeting it has notified to the exchanges.
How does the Marksans Pharma PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Marksans Pharma's PE ratio is 34.2, the lowest of the four: Granules India 34.9, Metropolis Healthcare 60.4 and Park Medi World 37.0, a peer average of 44.1. Each is the company's market capitalisation at that price divided by its FY26 net profit.
How does Marksans Pharma compare with its peers?
On FY26 consolidated figures, against Granules India, Metropolis Healthcare and Park Medi World: Marksans Pharma's operating margin of 17.0% is the second highest of the four (Granules India 16.6%, Metropolis Healthcare 16.2%, Park Medi World 22.7%; peer average 18.5%); its return on equity of 25.6% is the highest of the four (Granules India 13.5%, Metropolis Healthcare 13.4%, Park Medi World 12.8%; peer average 13.2%).
Marksans Pharma vs Granules India: how do they compare?
In FY26, Marksans Pharma earned net profit attributable to shareholders of ₹418 crore on revenue of ₹2,951 crore, against ₹595 crore on ₹5,366 crore for Granules India. Marksans Pharma's operating margin was 17.0% (Granules India 16.6%) and its return on equity 25.6% (Granules India 13.5%). At the 29 October 2026 close, Marksans Pharma's market capitalisation was ₹14,290 crore against ₹20,750 crore for Granules India, and its PE ratio on FY26 profit 34.2 against 34.9.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
